Study of AZD8931 in Patients With Advanced Solid Malignancies

Phase 1 Completed 41 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies

Timeline

Start: 2008-02
Primary completion: 2009-06
Completion: 2012-12

Publications

Tjulandin S, Moiseyenko V, Semiglazov V, Manikhas G, Learoyd M, Saunders A, Stuart M, Keilholz U. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):145-53. doi: 10.1007/s10637-013-9963-6. Epub 2013 Apr 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SAPITINIB	Small molecule	40 mg	Oral
Subject	SAPITINIB	Small molecule	80 mg	Oral
Subject	SAPITINIB	Small molecule	160 mg	Oral
Subject	SAPITINIB	Small molecule	240 mg	Oral
Subject	SAPITINIB	Small molecule	300 mg	Oral

Study of AZD8931 in Patients With Advanced Solid Malignancies

Summary

Timeline

Publications

Drugs

Indications